BRPI0508791A - composto, composição farmacêutica, uso do composto, método para elevar o hdl em um indivìduo, método para o tratamento de diabetes do tipo 2, resistência à insulina diminuìda ou redução da pressão do sangue em um indivìduo, método para diminuir o ldlc em um indivìduo, método para deslocar o tamanho de partìcula de ldl denso pequeno a ldl normal em um indivìduo, método para o tratamento de doenças ateroscleróticas incluindo doença vascular, doença das coronárias do coração, doença cerebrovascular e doença de vaso periférico em um indivìduo, método para o tratamento de doenças inflamatórias, incluindo a artrite reumatoide, a asma, a osteodistrofia e doença autoimune em um individuo, metodo de tratamento de uma doença ou condição medida por hppar-delta, método de modulação de uma função de receptor ativada por proliferador de peroxisoma (ppar), e método de tratamento de uma doença ou uma condição - Google Patents

composto, composição farmacêutica, uso do composto, método para elevar o hdl em um indivìduo, método para o tratamento de diabetes do tipo 2, resistência à insulina diminuìda ou redução da pressão do sangue em um indivìduo, método para diminuir o ldlc em um indivìduo, método para deslocar o tamanho de partìcula de ldl denso pequeno a ldl normal em um indivìduo, método para o tratamento de doenças ateroscleróticas incluindo doença vascular, doença das coronárias do coração, doença cerebrovascular e doença de vaso periférico em um indivìduo, método para o tratamento de doenças inflamatórias, incluindo a artrite reumatoide, a asma, a osteodistrofia e doença autoimune em um individuo, metodo de tratamento de uma doença ou condição medida por hppar-delta, método de modulação de uma função de receptor ativada por proliferador de peroxisoma (ppar), e método de tratamento de uma doença ou uma condição

Info

Publication number
BRPI0508791A
BRPI0508791A BRPI0508791-0A BRPI0508791A BRPI0508791A BR PI0508791 A BRPI0508791 A BR PI0508791A BR PI0508791 A BRPI0508791 A BR PI0508791A BR PI0508791 A BRPI0508791 A BR PI0508791A
Authority
BR
Brazil
Prior art keywords
disease
individual
treating
condition
compound
Prior art date
Application number
BRPI0508791-0A
Other languages
English (en)
Inventor
Cunxiang Zhao
James W Malecha
Stewart A Noble
Sergio Gonzalez Duron
Andrew Kenneth Lindstrom
Andrew K Shiau
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of BRPI0508791A publication Critical patent/BRPI0508791A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DO COMPOSTO, MéTODO PARA ELEVAR O HDL EM UM INDIVìDUO, MéTODO PARA O TRATAMENTO DE DIABETES DO TIPO 2, RESISTêNCIA à INSULINA DIMINUìDA OU REDUçãO DA PRESSãO DO SANGUE EM UM INDIVìDUO, MéTODO PARA DIMINUIR O LDLC EM UM INDIVìDUO. MéTODO PARA DESLOCAR O TAMANHO DE PARTìCULA DE LDL DENSO PEQUENO A LDL NORMAL EM UM INDIVìDUO, MéTODO PARA O TRATAMENTO DE DOENçAS ATEROSCLERóTICAS INCLUINDO DOENçA VASCULAR, DOENçA DAS CORONáRIAS DO CORAçãO, DOENçA CEREBROVASCULAR E DOENçA DE VASO PERIFéRICO EM UM INDIVìDUO, MéTODO PARA O TRATAMENTO DE DOENçAS INFLAMATóRIAS, INCLUINDO A ARTRITE REUMATOIDE, A ASMA, A OSTEODISTROFIA E DOENçA AUTOIMUNE EM UM INDIVìDUO, MéTODO DE TRATAMENTO DE UMA DOENçA OU CONDIçãO MEDIDA POR hPPAR-delta, MéTODO DE MODULAçãO DE UMA FUNçãO DE RECEPTOR ATIVADA POR PROLIFERADOR DE PEROXISOMA (PPAR), E MéTODO DE TRATAMENTO DE UMA DOENçA OU UMA CONDIçãO Trata-se de compostos de aril sulfonamida e sulfonila da fórmula (I) como moduladores de receptores ativados por proliferador de peroxisoma, composições farmacêuticas que compreendem os mesmos e métodos de tratamento de doença que utilizam os mesmos.
BRPI0508791-0A 2004-04-07 2005-04-07 composto, composição farmacêutica, uso do composto, método para elevar o hdl em um indivìduo, método para o tratamento de diabetes do tipo 2, resistência à insulina diminuìda ou redução da pressão do sangue em um indivìduo, método para diminuir o ldlc em um indivìduo, método para deslocar o tamanho de partìcula de ldl denso pequeno a ldl normal em um indivìduo, método para o tratamento de doenças ateroscleróticas incluindo doença vascular, doença das coronárias do coração, doença cerebrovascular e doença de vaso periférico em um indivìduo, método para o tratamento de doenças inflamatórias, incluindo a artrite reumatoide, a asma, a osteodistrofia e doença autoimune em um individuo, metodo de tratamento de uma doença ou condição medida por hppar-delta, método de modulação de uma função de receptor ativada por proliferador de peroxisoma (ppar), e método de tratamento de uma doença ou uma condição BRPI0508791A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56057904P 2004-04-07 2004-04-07
US65615705P 2005-02-24 2005-02-24
PCT/US2005/011751 WO2005115983A1 (en) 2004-04-07 2005-04-07 Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders

Publications (1)

Publication Number Publication Date
BRPI0508791A true BRPI0508791A (pt) 2007-09-04

Family

ID=34965955

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508791-0A BRPI0508791A (pt) 2004-04-07 2005-04-07 composto, composição farmacêutica, uso do composto, método para elevar o hdl em um indivìduo, método para o tratamento de diabetes do tipo 2, resistência à insulina diminuìda ou redução da pressão do sangue em um indivìduo, método para diminuir o ldlc em um indivìduo, método para deslocar o tamanho de partìcula de ldl denso pequeno a ldl normal em um indivìduo, método para o tratamento de doenças ateroscleróticas incluindo doença vascular, doença das coronárias do coração, doença cerebrovascular e doença de vaso periférico em um indivìduo, método para o tratamento de doenças inflamatórias, incluindo a artrite reumatoide, a asma, a osteodistrofia e doença autoimune em um individuo, metodo de tratamento de uma doença ou condição medida por hppar-delta, método de modulação de uma função de receptor ativada por proliferador de peroxisoma (ppar), e método de tratamento de uma doença ou uma condição

Country Status (11)

Country Link
US (1) US20050234046A1 (pt)
EP (1) EP1735280A1 (pt)
JP (1) JP2007532563A (pt)
KR (1) KR20060133095A (pt)
AR (1) AR048523A1 (pt)
AU (1) AU2005247855A1 (pt)
BR (1) BRPI0508791A (pt)
CA (1) CA2564638A1 (pt)
MX (1) MXPA06011691A (pt)
TW (1) TW200607491A (pt)
WO (1) WO2005115983A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US20070208026A1 (en) * 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
US20060258683A1 (en) * 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
TW200626139A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
BRPI0515483A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
AU2005286731A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
BRPI0515505A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
CN101090724A (zh) * 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
WO2006034312A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
BRPI0515489A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
BRPI0515488A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
AR052319A1 (es) 2004-10-29 2007-03-14 Kalypsys Inc Compuestos biciclicos sustituidos por sulfonilo en funcion de moduladores del ppar
WO2007130075A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
AU2006282403B2 (en) 2005-08-26 2011-07-07 Institute Of Medicinal Molecular Design, Inc. Derivative having PPAR agonistic activity
EP1940767A2 (en) * 2005-09-07 2008-07-09 Plexxikon, Inc. Pparactive compounds
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
WO2007047431A2 (en) * 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors
WO2007047432A1 (en) * 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonamide derivatives as modulators of ppar
WO2007051095A1 (en) 2005-10-25 2007-05-03 Kalypsys, Inc. Salts of modulators of ppar and methods of treating metabolic disorders
JP2009519933A (ja) * 2005-12-14 2009-05-21 アムゲン インコーポレイティッド ジアザ複素環式スルホンアミド誘導体およびそれらの使用法
CA2641609A1 (en) * 2006-02-07 2007-08-16 Wyeth 11-beta hsd1 inhibitors
JP2009531447A (ja) * 2006-03-29 2009-09-03 メルク エンド カムパニー インコーポレーテッド ジアゼパンオレキシン受容体アンタゴニスト
US20070249519A1 (en) * 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
WO2007122411A1 (en) * 2006-04-26 2007-11-01 Astrazeneca Ab Diazepan-1-yl-sulfonyl derivatives for the treatment of metabolic syndrome
TW200745059A (en) * 2006-05-16 2007-12-16 Kalypsys Inc Sulfonyl-substituted bicyclic compounds as modulators of PPAR
JP2009539880A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Ｄｐ−２アンタゴニストとしての置換フェニル酢酸
US20080176861A1 (en) * 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
JP2008239616A (ja) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Ｈｄｌ上昇剤
CN103265501B (zh) * 2007-03-27 2015-06-03 盐野义制药株式会社 N-苯基-n’-苯磺酰基哌嗪衍生物的制造方法
WO2008130718A1 (en) * 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
WO2008152650A1 (en) * 2007-06-15 2008-12-18 Symed Labs Limited Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates
EP2188272B1 (en) * 2007-08-06 2016-02-24 reMynd NV Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases
WO2011058915A1 (ja) * 2009-11-13 2011-05-19 住友精化株式会社 芳香族スルホニルクロライド化合物の製造方法
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
CN104926804B (zh) * 2015-06-04 2019-01-25 天津渤海职业技术学院 一类具有抗肿瘤作用的化合物、其制备方法和用途
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
ES2877763T3 (es) 2016-09-20 2021-11-17 Glaxosmithkline Ip No 2 Ltd Antagonistas del trpv4
JP7268049B2 (ja) 2018-03-08 2023-05-02 インサイト・コーポレイション ＰＩ３Ｋ－γ阻害剤としてのアミノピラジンジオール化合物
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
US11866446B2 (en) 2020-08-26 2024-01-09 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CN113512004B (zh) * 2021-07-22 2022-08-05 金凯(辽宁)生命科技股份有限公司 一种2-氟-5-三氟甲基嘧啶的合成方法
WO2023154310A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
EP1048652A4 (en) * 1997-12-26 2001-05-09 Mochida Pharm Co Ltd AROMATIC COMPOUNDS WITH A CYCLIC AMINO GROUP OR THEIR SALTS
EP1163213A1 (en) * 1999-03-22 2001-12-19 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB0007907D0 (en) * 2000-03-31 2000-05-17 Merck Sharp & Dohme Therapeutic agents
AU2001290131B2 (en) * 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
DE10222034A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
GB0214149D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
AU2003259301A1 (en) * 2002-07-29 2004-02-16 Ast Products, Inc. Ophtalmic compositions
US20060258683A1 (en) * 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
DE602004012083T2 (de) * 2003-04-15 2009-04-23 Astrazeneca Ab Neue Verbindungen, die als Verstärker von Glutamatrezeptoren dienen
US6852713B2 (en) * 2003-04-16 2005-02-08 Adolor Corporation Lactam derivatives and methods of their use

Also Published As

Publication number Publication date
KR20060133095A (ko) 2006-12-22
US20050234046A1 (en) 2005-10-20
MXPA06011691A (es) 2007-01-23
WO2005115983A1 (en) 2005-12-08
JP2007532563A (ja) 2007-11-15
EP1735280A1 (en) 2006-12-27
CA2564638A1 (en) 2005-12-08
TW200607491A (en) 2006-03-01
AU2005247855A1 (en) 2005-12-08
AR048523A1 (es) 2006-05-03

Similar Documents

Publication Publication Date Title
BRPI0508791A (pt) composto, composição farmacêutica, uso do composto, método para elevar o hdl em um indivìduo, método para o tratamento de diabetes do tipo 2, resistência à insulina diminuìda ou redução da pressão do sangue em um indivìduo, método para diminuir o ldlc em um indivìduo, método para deslocar o tamanho de partìcula de ldl denso pequeno a ldl normal em um indivìduo, método para o tratamento de doenças ateroscleróticas incluindo doença vascular, doença das coronárias do coração, doença cerebrovascular e doença de vaso periférico em um indivìduo, método para o tratamento de doenças inflamatórias, incluindo a artrite reumatoide, a asma, a osteodistrofia e doença autoimune em um individuo, metodo de tratamento de uma doença ou condição medida por hppar-delta, método de modulação de uma função de receptor ativada por proliferador de peroxisoma (ppar), e método de tratamento de uma doença ou uma condição
Mohler III et al. Bone formation and inflammation in cardiac valves
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
Sattui et al. Fracture mortality: associations with epidemiology and osteoporosis treatment
Gupta et al. Nanoscale deformation mechanisms in bone
Muramatsu et al. Musculoskeletal sarcomas in the forearm and hand: standard treatment and microsurgical reconstruction for limb salvage
CL2007001869A1 (es) Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e
BR112019002245A2 (pt) agonistas de receptor acoplado à proteína g
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
Nowaczyk et al. Overview of first-line and second-line pharmacotherapies for osteoarthritis with special focus on intra-articular treatment
UY30229A1 (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
Hutcheson et al. Cardiovascular calcification heterogeneity in chronic kidney disease
BR112018067969A2 (pt) uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica
Palikova et al. Long-term effects of three commercial cranberry products on the antioxidative status in rats: a pilot study
Weng et al. Propolin H from Taiwanese propolis induces G1 arrest in human lung carcinoma cells
Farnham et al. Lubricant effects on articular cartilage sliding biomechanics under physiological fluid load support
BR112017003983A2 (pt) ?terapêutica com anticorpos que se ligam a oprf e oprl?
Costăchescu et al. Recent advances in managing spinal intervertebral discs degeneration
BRPI0515329A (pt) ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos
PL1951692T3 (pl) Oksazolowe i tiazolowe modulatory PPAR
Leone et al. Rehabilitation: Neurogenic Bone Loss after Spinal Cord Injury
Scoccianti et al. Total calcanectomy and reconstruction with vascularized iliac bone graft for osteoblastoma: a report of two cases
Kwan et al. Effect of Aging on Tendon Biology, Biomechanics and Implications for Treatment Approaches
AR069639A1 (es) Composicion de nanoparticulas con superficie modificada
Sharma et al. Pinus roxburghii alleviates bone porosity and loss in postmenopausal osteoporosis by regulating estrogen, calcium homeostasis and receptor activator of nuclear factor-κB, osteoprotegerin, cathepsin bone markers

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.